An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Clinical trial NCT05011058 · TERMINATED

Trial details

NCT number: NCT05011058
Sponsor: Viracta Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Epstein-Barr Virus Associated Lymphoma EBV-Positive DLBCL, NOS EBV-Related Non-Hodgkin Lymphoma EBV Related PTCL, NOS EBV-Related Hodgkin Lymphoma EBV-Related PTLD EBV-Related Lymphoproliferative Disorder

Start date: 2021-05-28
Primary completion: 2024-12-26
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.